Please enable JavaScript to continue using this application.

Compare $GRAL vs $IMVT | Chartloom

Compare

$GRAL vs $IMVT

Grail Inc · Immunovant Inc

GRAL

Grail Inc

IMVT

Immunovant Inc

Compare $GRAL vs $IMVT

Comparing Grail Inc and Immunovant Inc

GRALGrail Inc

IMVTImmunovant Inc

GRALGrail Inc

Market cap

$6.03B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

29.71x

Rev growth (TTM)

23.1%

YTD performance

58.2%

52W performance

123.8%

FCF yield

-4.9%

IMVTImmunovant Inc

Market cap

$6.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

17.6%

52W performance

89.5%

FCF yield

-6.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GRAL

IMVT

Detailed metrics comparison

GRAL

Grail Inc

IMVT

Immunovant Inc

Market Cap

GRAL$6.03B

IMVT$6.29B

Enterprise Value

GRAL$5.98B

IMVT$5.49B

Price

GRAL$140.58

IMVT$30.47

P/E Ratio

GRALN/A

IMVTN/A

P/S Ratio

GRAL36.51x

IMVT0.00x

EV/Sales

GRAL36.17x

IMVT0.00x

EV/EBITDA

GRAL0.00x

IMVT0.00x

P/B Ratio

GRAL2.52x

IMVT9.44x

P/FCF Ratio

GRALN/A

IMVTN/A

EV/FCF

GRAL-20.19x

IMVT-13.25x

PEG Ratio

GRALN/A

IMVTN/A

Forward P/E (NTM)

GRALN/A

IMVTN/A

Forward P/S (NTM)

GRAL29.71x

IMVTN/A

Revenue (TTM)

GRAL$165M

IMVT$0

Revenue Growth (YoY)

GRAL23.1%

IMVTN/A

Forward Rev Growth

GRAL25.3%

IMVT546.2%

Gross Margin (TTM)

GRAL49.7%

IMVT0.0%

Operating Margin (TTM)

GRAL0.0%

IMVT0.0%

EBITDA Margin (TTM)

GRAL-229.0%

IMVT0.0%

Net Margin (TTM)

GRAL-236.9%

IMVT0.0%

FCF Margin (TTM)

GRAL-179.2%

IMVTN/A

Net Income (TTM)

GRAL$-392M

IMVT$-538M

FCF (TTM)

GRAL$-296M

IMVT$-414M

EPS (TTM)

GRAL-$9.08

IMVT-$2.62

ROE (TTM)

GRAL-1588.0%

IMVT-6959.0%

ROA (TTM)

GRAL-1402.0%

IMVT-6250.0%

ROIC (TTM)

GRAL-1588.0%

IMVT-6959.0%

Cash

GRAL$56M

IMVT$798M

Debt

GRAL$0

IMVT$0

Net Cash/Debt

GRAL$56M

IMVT$798M

Current Ratio (TTM)

GRAL10.95x

IMVT7.27x

Quick Ratio (TTM)

GRAL10.55x

IMVT6.82x

Debt/Equity (TTM)

GRAL0.00x

IMVT0.00x

Debt/Assets (TTM)

GRAL0.0%

IMVT0.0%

Interest Coverage (TTM)

GRALN/A

IMVTN/A

Net Debt/EBITDA (TTM)

GRAL0.00x

IMVT0.00x

Beta

GRAL2.04

IMVT0.92

52W Performance

GRAL123.8%

IMVT89.5%

YTD Performance

GRAL58.2%

IMVT17.6%

% from 52W High

GRAL-15.6%

IMVT-32.9%

% from 52W Low

GRAL238.7%

IMVT89.5%

Asset Turnover (TTM)

GRAL0.06x

IMVT0.00x

FCF Yield (TTM)

GRAL-4.9%

IMVT-6.6%

Earnings Yield (TTM)

GRAL-6.5%

IMVT-8.6%

Dividend Yield (TTM)

GRALN/A

IMVTN/A

Rule of 40

GRAL-156.1

IMVT0.0

EV/GP/RG

GRAL2.75

IMVTN/A

Ticker research

View GRAL research View IMVT research

Metric	GRAL Grail Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$6.03B	$6.29B
Enterprise Value	$5.98B	$5.49B
Price	$140.58	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	36.51x	0.00x
EV/Sales	36.17x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.52x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	29.71x	N/A
Revenue & Growth
Revenue (TTM)	$165M	$0
Revenue Growth (YoY)	23.1%	N/A
Forward Rev Growth	25.3%	546.2%
Profitability
Gross Margin (TTM)	49.7%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-229.0%	0.0%
Net Margin (TTM)	-236.9%	0.0%
FCF Margin (TTM)	-179.2%	N/A
Net Income (TTM)	$-392M	$-538M
FCF (TTM)	$-296M	$-414M
EPS (TTM)	-$9.08	-$2.62
ROE (TTM)	-1588.0%	-6959.0%
ROA (TTM)	-1402.0%	-6250.0%
ROIC (TTM)	-1588.0%	-6959.0%
Financial Health
Cash	$56M	$798M
Debt	$0	$0
Net Cash/Debt	$56M	$798M
Current Ratio (TTM)	10.95x	7.27x
Quick Ratio (TTM)	10.55x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	0.92
52W Performance	123.8%	89.5%
YTD Performance	58.2%	17.6%
% from 52W High	-15.6%	-32.9%
% from 52W Low	238.7%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-4.9%	-6.6%
Earnings Yield (TTM)	-6.5%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-156.1	0.0
EV/GP/RG	2.75	N/A
Ticker research	View GRAL research	View IMVT research

Valuation

P/S Ratio

IMVT

0.00x

GRAL

36.51x

EV/FCF

GRAL

-20.19x

IMVT

-13.25x

Growth & revenue

Revenue Growth TTM

GRAL

23.1%

Forward Revenue Growth

IMVT

546.2%

GRAL

25.3%

Profitability & performance

Gross Margin

GRAL

49.7%

IMVT

0.0%

ROE

GRAL

-1588.0%

IMVT

-6959.0%

FCF Yield %

GRAL

-4.9%

IMVT

-6.6%

52-Week Performance

GRAL

123.8%

IMVT

89.5%

Detailed metrics comparison

GRAL

Grail Inc

IMVT

Immunovant Inc

Market Cap

GRAL$6.03B

IMVT$6.29B

Enterprise Value

GRAL$5.98B

IMVT$5.49B

Price

GRAL$140.58

IMVT$30.47

P/E Ratio

GRALN/A

IMVTN/A

P/S Ratio

GRAL36.51x

IMVT0.00x

EV/Sales

GRAL36.17x

IMVT0.00x

EV/EBITDA

GRAL0.00x

IMVT0.00x

P/B Ratio

GRAL2.52x

IMVT9.44x

P/FCF Ratio

GRALN/A

IMVTN/A

EV/FCF

GRAL-20.19x

IMVT-13.25x

PEG Ratio

GRALN/A

IMVTN/A

Forward P/E (NTM)

GRALN/A

IMVTN/A

Forward P/S (NTM)

GRAL29.71x

IMVTN/A

Revenue (TTM)

GRAL$165M

IMVT$0

Revenue Growth (YoY)

GRAL23.1%

IMVTN/A

Forward Rev Growth

GRAL25.3%

IMVT546.2%

Gross Margin (TTM)

GRAL49.7%

IMVT0.0%

Operating Margin (TTM)

GRAL0.0%

IMVT0.0%

EBITDA Margin (TTM)

GRAL-229.0%

IMVT0.0%

Net Margin (TTM)

GRAL-236.9%

IMVT0.0%

FCF Margin (TTM)

GRAL-179.2%

IMVTN/A

Net Income (TTM)

GRAL$-392M

IMVT$-538M

FCF (TTM)

GRAL$-296M

IMVT$-414M

EPS (TTM)

GRAL-$9.08

IMVT-$2.62

ROE (TTM)

GRAL-1588.0%

IMVT-6959.0%

ROA (TTM)

GRAL-1402.0%

IMVT-6250.0%

ROIC (TTM)

GRAL-1588.0%

IMVT-6959.0%

Cash

GRAL$56M

IMVT$798M

Debt

GRAL$0

IMVT$0

Net Cash/Debt

GRAL$56M

IMVT$798M

Current Ratio (TTM)

GRAL10.95x

IMVT7.27x

Quick Ratio (TTM)

GRAL10.55x

IMVT6.82x

Debt/Equity (TTM)

GRAL0.00x

IMVT0.00x

Debt/Assets (TTM)

GRAL0.0%

IMVT0.0%

Interest Coverage (TTM)

GRALN/A

IMVTN/A

Net Debt/EBITDA (TTM)

GRAL0.00x

IMVT0.00x

Beta

GRAL2.04

IMVT0.92

52W Performance

GRAL123.8%

IMVT89.5%

YTD Performance

GRAL58.2%

IMVT17.6%

% from 52W High

GRAL-15.6%

IMVT-32.9%

% from 52W Low

GRAL238.7%

IMVT89.5%

Asset Turnover (TTM)

GRAL0.06x

IMVT0.00x

FCF Yield (TTM)

GRAL-4.9%

IMVT-6.6%

Earnings Yield (TTM)

GRAL-6.5%

IMVT-8.6%

Dividend Yield (TTM)

GRALN/A

IMVTN/A

Rule of 40

GRAL-156.1

IMVT0.0

EV/GP/RG

GRAL2.75

IMVTN/A

Ticker research

View GRAL research View IMVT research

Metric	GRAL Grail Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$6.03B	$6.29B
Enterprise Value	$5.98B	$5.49B
Price	$140.58	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	36.51x	0.00x
EV/Sales	36.17x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.52x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	29.71x	N/A
Revenue & Growth
Revenue (TTM)	$165M	$0
Revenue Growth (YoY)	23.1%	N/A
Forward Rev Growth	25.3%	546.2%
Profitability
Gross Margin (TTM)	49.7%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-229.0%	0.0%
Net Margin (TTM)	-236.9%	0.0%
FCF Margin (TTM)	-179.2%	N/A
Net Income (TTM)	$-392M	$-538M
FCF (TTM)	$-296M	$-414M
EPS (TTM)	-$9.08	-$2.62
ROE (TTM)	-1588.0%	-6959.0%
ROA (TTM)	-1402.0%	-6250.0%
ROIC (TTM)	-1588.0%	-6959.0%
Financial Health
Cash	$56M	$798M
Debt	$0	$0
Net Cash/Debt	$56M	$798M
Current Ratio (TTM)	10.95x	7.27x
Quick Ratio (TTM)	10.55x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	0.92
52W Performance	123.8%	89.5%
YTD Performance	58.2%	17.6%
% from 52W High	-15.6%	-32.9%
% from 52W Low	238.7%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-4.9%	-6.6%
Earnings Yield (TTM)	-6.5%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-156.1	0.0
EV/GP/RG	2.75	N/A
Ticker research	View GRAL research	View IMVT research